Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3945033
Max Phase: Preclinical
Molecular Formula: C44H50ClN9O6S
Molecular Weight: 868.46
Molecule Type: Small molecule
Associated Items:
ID: ALA3945033
Max Phase: Preclinical
Molecular Formula: C44H50ClN9O6S
Molecular Weight: 868.46
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN1CCN(Nc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cccc4[nH]cnc34)cc2[N+](=O)[O-])CC1
Standard InChI: InChI=1S/C44H50ClN9O6S/c1-44(2)16-15-31(36(27-44)30-7-9-32(45)10-8-30)28-51-19-21-52(22-20-51)33-11-13-35(41(25-33)60-40-6-4-5-38-42(40)47-29-46-38)43(55)49-61(58,59)34-12-14-37(39(26-34)54(56)57)48-53-23-17-50(3)18-24-53/h4-14,25-26,29,48H,15-24,27-28H2,1-3H3,(H,46,47)(H,49,55)
Standard InChI Key: JLJXTTBIPXLTSF-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 868.46 | Molecular Weight (Monoisotopic): 867.3293 | AlogP: 7.40 | #Rotatable Bonds: 12 |
Polar Surface Area: 169.28 | Molecular Species: ACID | HBA: 12 | HBD: 3 |
#RO5 Violations: 3 | HBA (Lipinski): 15 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 4.15 | CX Basic pKa: 7.95 | CX LogP: 6.13 | CX LogD: 6.33 |
Aromatic Rings: 5 | Heavy Atoms: 61 | QED Weighted: 0.08 | Np Likeness Score: -1.03 |
1. (2015) Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases, |
Source(1):